Pembrolizumab related osteonecrosis of the jaw.
Immunotherapy
Medication related osteonecrosis of the jaw
Pembrolizumab
Journal
The British journal of oral & maxillofacial surgery
ISSN: 1532-1940
Titre abrégé: Br J Oral Maxillofac Surg
Pays: Scotland
ID NLM: 8405235
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
11
08
2023
accepted:
29
08
2023
pubmed:
14
11
2023
medline:
14
11
2023
entrez:
13
11
2023
Statut:
ppublish
Résumé
Medication related osteonecrosis of the jaw (MRONJ) is a serious complication with potential implications on patients' ongoing medical care. This case report describes a case of MRONJ from pembrolizumab; a novel immune checkpoint inhibitor drug.
Identifiants
pubmed: 37957097
pii: S0266-4356(23)00486-2
doi: 10.1016/j.bjoms.2023.08.241
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
704-706Informations de copyright
Copyright © 2023 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.